Amendment Flag
Current Fiscal Year End Date
Document Period End Date
Entity [Domain]
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Legal Entity [Axis]
Document Type
Award Type [Axis]
Summary of significant accounting policies [Abstract]
Accounts payable
Accounts Payable, Current
Accounts receivable, net
Accounts Receivable, Net, Current
Accrued expenses and other current liabilities
Royalty provisions
Accrued Royalties, Current
Less: Accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated other comprehensive loss
Intangible assets, weighted average useful life
Additional paid-in capital
Accumulated Amortization [Abstract]
Adjustments to reconcile to net cash provided by (used in) operating activities:
Adjustments for New Accounting Pronouncements [Axis]
Amortization of debt issuance costs, net of tax
Amortization
Amortization of Intangible Assets
Antidilutive Securities [Axis]
Antidilutive shares excluded from calculation (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Assets [Abstract]
Assets, Fair Value Disclosure [Abstract]
Total assets
Assets
ASSETS
Assets [Abstract]
Current assets of discontinued operations
Total assets
Assets, Fair Value Disclosure
Current assets:
Total current assets
Assets, Current
Buildings, Building Improvements and Leasehold Improvements [Member]
Business Acquisition [Axis]
Business Acquisition, Acquiree [Domain]
Total value of transaction
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Cash and cash equivalents at end of period
Cash and cash equivalents at beginning of period
Cash and Cash Equivalents, at Carrying Value
Net increase in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Investment in money market funds (1)
Cash and Cash Equivalents, Fair Value Disclosure
Net cash provided by financing activities
Net cash provided by investing activities
Net cash used in operating activities
Commitments and contingencies
Litigation [Abstract]
Common stock, shares issued (in shares)
Common stock, shares authorized (in shares)
Common stock, $0.001 par value; 200,000,000 shares authorized, 41,532,614 shares issued and 41,107,065 shares outstanding at June 30, 2017; 40,996,890 shares issued and 40,574,060 shares outstanding at December 31, 2016
Common stock, par value (in dollars per share)
Common stock, shares outstanding (in shares)
Comprehensive income (loss)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Software [Member]
Basis of presentation and consolidation
Construction-in-progress [Member]
Contract termination costs [Member]
Contracts and grants
Cost of product sales and contract manufacturing
Cost of Goods Sold
Debt Instrument [Axis]
Face amount of debt instrument
Debt Instrument, Name [Domain]
Interest rate percentage
Interest rate, stated percentage
Maturity date
Deferred revenue, current portion
Deferred income taxes
Deferred revenue
Deferred revenue, net of current portion
Deferred tax assets, net
Deferred Tax Assets, Net of Valuation Allowance, Noncurrent
Deferred tax assets, current portion, net
Deferred Tax Assets, Net of Valuation Allowance, Current
Deferred tax liability, net
Deferred tax liability-current portion, net
Depreciation and amortization
Equity awards
Equity awards [Abstract]
Income (loss) from discontinued operations before provision for (benefit from) income taxes
Discontinued Operations [Abstract]
Net loss per share from discontinued operations-diluted (in dollars per share)
Net loss per share from discontinued operations-diluted (in dollars per share)
Held-for-sale [Member]
Disposed of by Sale [Member]
TSA revenue from Aptevo
Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue
Net Income (loss) from discontinued operations
Discontinued Operation, Provision for Loss (Gain) on Disposal, Net of Tax
Provision for (benefit from) income taxes
Discontinued Operation, Tax (Expense) Benefit from Provision for (Gain) Loss on Disposal
Net loss per share from discontinued operations-basic (in dollars per share)
Net loss per share from discontinued operations-basic (in dollars per share)
Cost of product sales
Total revenues
Disposal Group, Including Discontinued Operation, Revenue
Disposal Group Classification [Domain]
Income (loss) from operations
Disposal Group, Including Discontinued Operation, Operating Income (Loss)
Disposal Group Classification [Axis]
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Non-current assets of discontinued operations
Disposal Group Name [Domain]
Discontinued operations
Net income (loss) per share - basic:
Net income (loss) per share - diluted:
Net income per share - basic (in dollars per share)
Net income (loss) per share - basic (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)
Net income (loss) per share - diluted (in dollars per share)
Earnings Per Share, Diluted
Earnings per share
Earnings Per Share [Text Block]
Earnings per share [Abstract]
Effect of exchange rate changes on cash and cash equivalents
Accrued compensation
Employee-related Liabilities, Current
Stock Options Member [Member]
Convertible debt [Member]
Excess tax benefits from stock-based compensation
Excess tax benefits from stock-based compensation
Excess Tax Benefit from Share-based Compensation, Operating Activities
Additions
Fair Value, Hierarchy [Axis]
Fair Value by Measurement Frequency [Axis]
Fair value measurements [Abstract]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]
Fair Value, Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance, beginning of period
Balance, end of period
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value
Fair Value, Measurements, Fair Value Hierarchy [Domain]
Transfers in/(out) of Level 3
Settlements
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Fair value measurements
Fair Value Disclosures [Text Block]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Inputs, Level 1 [Member]
Fair Value, Inputs, Level 2 [Member]
Unobservable Input Reconciliation [Roll Forward]
Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)
Expense included in earnings
Net book value of intangible assets
Accumulated Amortization, Beginning Balance
Accumulated Amortization, Ending Balance
Finite-Lived Intangible Assets, Accumulated Amortization
Intangible Assets, Ending Balance
Intangible Assets, Beginning Balance
Finite-Lived Intangible Assets, Gross
Furniture and Equipment [Member]
Furniture and Fixtures [Member]
Goodwill
Intangible assets, in-process research and development
Intangible assets and in-process research and development [Abstract]
Abandonment of equipment charge
Impaired Assets to be Disposed of by Method Other than Sale, Amount of Impairment Loss
Impairment of equipment charge
Impairment of Long-Lived Assets to be Disposed of
Impairment of in-process research and development
Net income (loss) per share from continuing operations-basic (in dollars per share)
Net income (loss) per share from continuing operations-basic (in dollars per share)
Income Statement Location [Axis]
Income (loss) from continuing operations before provision for (benefit from) income taxes
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Income Statement Location [Domain]
Net Loss from discontinued operations
Net Loss from discontinued operations
Net income (loss) from continuing operations - diluted (in dollars per share)
Net income (loss) from continuing operations - diluted (in dollars per share)
Provision for (benefit from) income taxes
Consolidated Statements of Operations (unaudited) [Abstract]
Disposal Groups, Including Discontinued Operations [Table]
Disposal Group Name [Axis]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income tax receivable, net
Net Income (loss) from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Income tax receivable, long-term
Income Taxes Receivable, Noncurrent
Accounts payable
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accrued expenses and other liabilities
Inventories
Increase (Decrease) in Inventories
Deferred revenue
Increase (Decrease) in Deferred Revenue
Income taxes
Increase (Decrease) in Income Taxes Receivable
Accrued compensation
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Dilutive securities-equity awards (in shares)
Dilutive securities-convertible debt
Intangible Assets [Abstract]
Cost Basis [Abstract]
Intangible assets, net
Interest expense
Interest Expense
Interest expense, net of tax
Interest Expense, Long-term Debt
Inventories
Total inventories
Inventory, Net
Finished goods
Inventories
Inventory Disclosure [Text Block]
Inventories [Abstract]
Work-in-process
Raw materials and supplies
Interest income
Land and Improvements [Member]
Litigation
Total liabilities
Liabilities
Non-current liabilities of discontinued operations
Current liabilities of discontinued operations
Total liabilities and stockholders' equity
Liabilities and Equity
LIABILITIES AND STOCKHOLDERS' EQUITY
Total liabilities
Financial and Nonfinancial Liabilities, Fair Value Disclosure
Liabilities [Abstract]
Total current liabilities
Liabilities, Current
Current liabilities:
License and Services Revenue
License and Services Revenue
Long-term indebtedness
Long-term Debt, Excluding Current Maturities
Maximum [Member]
Minimum [Member]
Net cash provided by operating activities
Net Cash Provided by (Used in) Operating Activities
Net increase in cash and cash equivalents
Net Cash Provided by (Used in) Discontinued Operations
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Cash flows from financing activities:
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities
Cash flows from investing activities:
Cash flows from operating activities:
Net income (loss)
Net income (loss)
Net Income (Loss) Attributable to Parent
Net cash (used in) provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Numerator [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic [Abstract]
New Accounting Pronouncements or Change in Accounting Principle [Table]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total other expense, net
Nonoperating Income (Expense)
Other income (expense):
Fair value of the notes
Notes payable, current portion
Number of business segments
Operating expenses:
Income (loss) from operations
Operating Income (Loss)
Foreign currency translations, net of tax
Other
Other Noncash Income (Expense)
Other Costs [Member]
Other assets
Other income (expense), net
Other liabilities
Products and Services [Domain]
Taxes paid on behalf of employees for equity activity
Payments Related to Tax Withholding for Share-based Compensation
Upfront cash payment
Amount paid
Payments for Restructuring
Acquisition of Cangene Corporation, net of acquired cash
Payments to Acquire Businesses, Net of Cash Acquired
Purchase of treasury stock
Payments for Repurchase of Common Stock
Purchases of property, plant and equipment
Payments to Acquire Property, Plant, and Equipment
Plan Name [Domain]
Plan Name [Axis]
Preferred stock, shares issued (in shares)
Preferred stock, shares authorized (in shares)
Preferred stock, par value (in dollars per share)
Preferred stock, shares outstanding (in shares)
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at both June 30, 2017 and December 31, 2016
Prepaid expenses and other current assets
Proceeds from convertible debenture, net of bank fees
Proceeds from Convertible Debt
Proceeds from long-term debt obligations
Issuance of common stock upon exercise of stock options
Product Information [Line Items]
Products and Services [Axis]
Net income (loss)
Property, Plant and Equipment, Type [Domain]
Property, plant and equipment [Abstract]
Property, plant and equipment
Property, Plant and Equipment [Table Text Block]
Property, plant and equipment, net
Total Property, plant and equipment, net
Property, Plant and Equipment [Line Items]
Property, plant and equipment
Property, Plant and Equipment, Gross
Property, Plant and Equipment, Type [Axis]
Property, plant and equipment
Property, Plant and Equipment Disclosure [Text Block]
Range [Axis]
Range [Domain]
Payments of notes payable
Repayments of Notes Payable
Research and development
Restricted Stock Units (RSUs) [Member]
Expenses incurred
Restructuring Charges
Balance, beginning of period
Balance, end of period
Restructuring Reserve
Restructuring Plan [Domain]
Restructuring Plan [Axis]
Incurred in 2017
Abandonment of equipment
Summary of activity for liabilities [Roll Forward]
Restructuring Type [Axis]
Total Expected to be Incurred
Restructuring Cost and Reserve [Line Items]
Restructuring
Restructuring and Related Activities Disclosure [Text Block]
Other adjustments
Retained earnings
Subsegments [Axis]
Subsegments [Domain]
Exercisable, end of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Aggregate intrinsic value [Abstract]
Outstanding, end of period
Outstanding, beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Revenues:
Total revenues
Revenue, Net
Product sales
Billed revenue amount
Inventories
Schedule of Inventory, Current [Table Text Block]
Restricted Stock Units Activity
Option Award Activity
Schedule of Product Information [Table]
Schedule of Product Information [Table]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Summary of Basic and Diluted Net Income (Loss) per Share
Property, Plant and Equipment [Table]
Schedule of Restructuring and Related Costs [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Costs of the restructuring
Summary of the activity for liabilities related to EBOL restructuring
Segments [Domain]
Segments [Domain]
Segment Reporting Information [Line Items]
Selling, general and administrative
Selling, General and Administrative Expense
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense
Granted (in dollars per share)
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-Average Grant Price [Roll Forward]
Exercised (in dollars per share)
Granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Restricted stock unit award activity [Roll Forward]
Cancelled (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee
Equitable adjustment (in dollars per share)
Weighted-Average Exercise Price [Roll Forward]
Granted (in shares)
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Cancelled (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Outstanding, end of period (in dollars per share)
Outstanding, beginning of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Outstanding, end of period (in shares)
Outstanding, beginning of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Exercisable, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Exercisable, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Aggregate Intrinsic Value [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Vested (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Outstanding, beginning of period (in dollars per share)
Outstanding, end of period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Outstanding, beginning of period (in shares)
Outstanding, end of period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Award Type [Domain]
Outstanding, end of period
Outstanding, beginning of period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Options outstanding [Roll Forward]
Equitable adjustment (in shares)
Summary of significant accounting policies
Significant Accounting Policies [Text Block]
Termination Benefits [Member]
Consolidated Statements of Cash Flows (Unaudited) [Abstract]
Consolidated Statements of Comprehensive Income (Loss) [Abstract]
Consolidated Balance Sheets (unaudited) [Abstract]
Segments [Axis]
Segments [Axis]
Stock Repurchase Program, Authorized Amount
Stock Options [Member]
Stock Compensation Plan [Member]
Exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Stockholders' equity:
Total stockholders' equity
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Subsequent events [Abstract]
Subsequent Event [Member]
Subsequent events
Subsequent Event Type [Axis]
Subsequent Event [Line Items]
Subsequent Event [Table]
Subsequent Event Type [Domain]
Treasury stock ( in shares)
Treasury stock, at cost, 425,549 and 422,830 common shares at June 30, 2017 and December 31, 2016, respectively
Treasury Stock, Value
Type of Restructuring [Domain]
Type of Adoption [Domain]
Unsecured debt
Unsecured Debt
Weighted-average number of shares - diluted (in shares)
Weighted-average number of shares-diluted (in shares)
Denominator [Abstract]
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted-average number of shares - basic (in shares)
Weighted-average number of shares-basic (in shares)
Amount for deliveries of product to the Strategic National Stockpile ("SNS").
Amount for deliveries of product
Amount for deliveries of product to the SNS
Business acquisition in July 2017.
GSK [Member]
Refers to the value of contract.
Value of contract
Term of contract under acquisition.
Term of contract under acquisition
The cash outflow associated with manufacturing related milestones.
Amount of payment for manufacturing related milestones
Business acquisition in July 2017.
Sanofi [Member]
Refers to Centers for Disease Control and Prevention
CDC [Member]
Amount of revenue from manufacturing services.
Manufacturing services revenue
Term of agreement to provide transitional services following the date of distribution.
Term of transition services agreement
Term of manufacturing services contract commencing on the date of distribution.
Term of manufacturing services contract
Disposal Group Including Discontinued Operation Nonoperating Income Expense [Abstract]
Other income (expense), net [Abstract]
Amount of selling, general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Selling General And Administrative Expense
Selling, general and administrative
Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Research And Development
Research and development
Disposal Group Including Discontinued Operation Operating Expenses [Abstract]
Operating expense [Abstract]
Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other attributable to disposal group, including, but not limited to, discontinued operation.
Disposal Group Including Discontinued Operation Contracts Revenue
Contracts, grants and collaborations
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts attributable to disposal group, including but not limited to, discontinued operations.
Disposal Group Including Discontinued Operation Sales Revenue Goods Net
Product sales
Disposal Group Not Discontinued Operation Income Statement Sales Revenue [Abstract]
Revenues [Abstract]
Percentage Of Outstanding Shares Distributed
Percentage Of Outstanding Shares Distributed
Percentage of outstanding shares distributed
Shares issued in the distribution.
Number of common stock distributed
Number of common stock distributed (in shares)
Record Date
Record date for distribution
Record date for distribution
Disposal Group, Including Discontinued Operation, Other Income (Expense), Net
Disposal Group Including Discontinued Operation Other Income (Expense) Net
Other income (expense), net
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Balance Sheet [Table Text Block]
Summarized results of discontinued operations included in consolidated statements of income
Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
Schedule Of Disposal Groups Including Discontinued Operations Cash Flow [Table Text Block]
Summary of disposal groups including discontinued operations cash flows
The amount of consideration allocated to delivery of the drug under the agreement.
Consideration Allocated To Delivery
Consideration allocated to procurement
The amount of consideration allocated to development activities for the drug under the agreement.
Consideration Allocated To Development Activities
Consideration allocated to development activities
Deferred revenue expressed as a percentage of the total amount of revenue received.
Percentage consideration revenue deferred
Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.
Accounting Standards Update 201609 [Member]
Accounting Standards Update 2016-09 [Member]
Refers to NuThrax which is sold by the company.
Biothrax [Member]
BioThrax [Member]
Refers to the Biomedical Advanced Research and Development Authority (BARDA).
BARDA [Member]
Refers to NuThrax which is sold by the company.
NuThrax [Member]
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax benefit from stock based compensation activity.
Effective Income Tax Rate Reconciliation, Tax Benefit with Stock Option Activity
Tax benefit associated with stock option activity
Total contract value after consideration of discount.
Total contract value
Discount on purchase price for doses to be procured.
Discount on purchase price for doses to be procured
Number of doses to be delivered under the contract.
Number of doses to be delivered
Period of performance for delivery of BioThrax.
Period of performance
Amount of contract with BARDA for the delivery of BioThrax.
Amount of contract
Refers to the number of publicly traded companies into which entity is separated.
Number of Independent Public Traded Entities
Number of independent public companies
The portion of profit or loss for the period, adjusted from continuing operations.
Net income, adjusted from continuing operations
Net income (loss), adjusted from continuing operations
The portion of profit or loss for the period, net of income taxes and other adjustments.
Adjusted net loss
Net income (loss), adjusted
Restructuring cost related to abandonment of equipment.
Abandonment of Equipment [Member]
A plan adopted by the Company in August 2016 to restructure and reprioritize the operations of Emergent BioDefense Operations Lansing LLC ("EBOL").
EBOL Restructuring Plan [Member]
Cumulative amount of costs incurred from inception to date for the specified restructuring cost.
Restructuring And Related Cost Cost Incurred Inception To Date
Inception to Date Costs Incurred
Document and Entity Information [Abstract]
Debt instrument dated January 2014 due 2021.
Convertible Senior Notes Due 2021 [Member]
Refers to the contingent value rights based on the novation of the contract with an agency.
Contingent value rights based on the novation of the contract
Selling, General and Administrative expense related to EV-035 & Unither contingent consideration.
EV-035&Unither Selling, General and Administrative Member [Member]
EV-035&Broad Spectrum Antiviral Platform Selling, General and Administrative Member [Member]
Research and development expense related to EV-035 and Unither contingent consideration.
EV-035 & Unither Research and Development [Member]
EV-035 & Broad Spectrum Antiviral Platform Research and Development [Member]
RSDL, a product of HPPD.
RSDL [Member]
This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents a type of right given to shareholders of an acquired company (or a company facing major restructuring) that ensures they receive additional benefit if a specified event occurs.
Contingent Value Rights, Fair Value Disclosure
Contingent consideration
Amount of purchases, sales, and issuances in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, Sales, Issues
Purchases, sales and issuances
Fair value measurement of contingent value rights granted to former shareholders and stock option holders of Bracco Diagnostics Inc. for net sales of RSDL.
Change In Fair Value Of Contingent Obligations
Change in fair value of contingent obligations
Refers to the products RSDL and HepaGam.
RSDL and HepaGam [Member]
Business acquisition in December 2014 and December 2015
Evolva Holding SA 035 & Unither [Member]
Evolva Holding SA 035 & Broad Spectrum Antiviral Platform [Member]
Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Aptevo [Member]
Aptevo [Member]
Segment of the Company which develops vaccines, antibody therapies and technology platforms for use against infectious diseases, oncology, autoimmune and inflammatory disorders and other medical conditions that have resulted in significant unmet or underserved public health needs.
Biosciences [Member]
Segment of the Company which develops, manufactures and commercializes vaccines and antibody therapies for use against biological agents that are potential weapons of bioterrorism or biowarfare.
Biodefense [Member]
A component of the Biosciences business segment.
Biosciences contracts manufacturing [Member]
Biosciences Contract Manufacturing [Member]
A component of the Biodefense segment.
Biodefense medical devices [Member]
Biodefense Medical Device [Member]
A component of the Biodefense segment.
Biodefense Vaccines and Therapeutics [Member]
Equitable adjustment of weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Equitable Adjustment Weighted Average Grant Date Fair Value
Equitable adjustment (in dollars per share)
Equitable adjustment of shares (or other type of equity) under an equity-based award plan, other than a stock option plan during the reporting period.
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Other Increases (Decreases) in Period
Equitable adjustment (in shares)
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired Weighted Average Grant Date Fair Value
Cancelled (in dollars per share)
The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period
Cancelled (in shares)
Refers to number of stock based employee compensation plans with the entity.
Number of Stock Compensation Plans
Number of stock-based employee compensation plans
A share-based compensation plan adopted by the Company in 2006.
Emergent BioSolutions Inc. 2006 Stock Incentive Plan [Member]
2006 Plan [Member]
A share-based compensation plan adopted by the Company in 2004.
Emergent BioSolutions Employee Stock Option Plan [Member]
2004 Plan [Member]
Revenue earned during the period arising from manufacturing sale under the terms of a contract.
Contract manufacturing
Contract manufacturing
Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the non current portion of the liabilities.
Accrued Royalties, Non Current
Royalty provisions, net of current portion
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Cash And Cash Equivalents Continuing Operations
Cash and cash equivalents
Carrying value as of the balance sheet date of the noncurrent portion of liabilities incurred and payable to former shareholders and stock option holders for certain developmental, regulatory or commercial milestones.
Contingent Consideration Net Of Current Portion
Contingent consideration, net of current portion
Carrying value as of the balance sheet date of the current portion of liabilities incurred and payable to former shareholders and stock option holders for certain developmental, regulatory or commercial milestones.
Contingent Consideration Current Portion
Contingent consideration, current portion
Current portion of the carrying values as of the balance sheet date of obligations incurred through that date and payable for chargebacks.
Provision for chargebacks
Carrying amount of purchased research and development assets acquired in a business combination that have an indefinite life until completion or abandonment of the associated research and development efforts.
In process research and development
Amount of cash outflow associated with the distribution of Aptevo common stock.
Distribution of Aptevo
Distribution to Aptevo
The cash outflow for contingent value rights.
Contingent value right payment
Contingent obligation payments
The provision charged to earnings in the period related to chargebacks obligations.
Provision for chargebacks, charged to earnings
Provision for chargebacks
Fair value measurement of contingent value rights and contingent purchase considerations granted under purchase agreements.
Change In Fair Value Of Contingent Consideration
Change in fair value of contingent obligations
Write-off of amounts previously recorded bank fees.
Write off of bank fees
Write off of debt issuance costs